COVID-19
Not recruitingStudy of GS-5245 for Treating COVID-19 in Children and Adolescents
Study of GS-5245 for Treating COVID-19 in Children and Adolescents
Hungary- Participants:0–17 years
- Substances:GS-5245
- Sponsor:Gilead Sciences Inc.
Rare diseases
Investigational molecules
Locations
Back to Hungary650 clinical trials in Berettyoujfalu, Hungary. Every trial is listed in the EU Clinical Trials Register and updated daily.
Study of GS-5245 for Treating COVID-19 in Children and Adolescents
HungaryStudy Comparing Enfortumab Vedotin and Pembrolizumab with Chemotherapy for Patients with Muscle-Invasive Bladder Cancer
HungaryStudy of Adagrasib Dosing in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation
HungaryStudy on the Effectiveness and Safety of SAR441566 for Adults with Moderate to Severe Plaque Psoriasis
HungaryStudy on the Effects of Zalunfiban for Patients with ST-Elevation Myocardial Infarction (Heart Attack)
HungaryStudy of Pembrolizumab, Cisplatin, and Gemcitabine for Patients with Muscle-Invasive Bladder Cancer Eligible for Cisplatin Treatment
HungaryStudy of Venetoclax and Azacitidine for Patients with Acute Myeloid Leukemia After Stem Cell Transplant
HungaryStudy of Tafasitamab, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma
HungaryStudy on the Effects of AZD0780 on Cholesterol Levels in Adults Aged 18-75 with Dyslipidemia
HungaryStudy on Guselkumab and Etanercept for Treating Chronic Plaque Psoriasis in Children Aged 6 to 17 Years
HungaryStudy on Baricitinib for Hospitalized Patients with Severe or Critical COVID-19
HungaryStudy of CGT9486 and Sunitinib for Patients with Advanced Gastrointestinal Stromal Tumors
HungaryThe busiest research cities in the country
What the registry says about research in the country
Innovative clinical trials focusing on primary prevention of atherosclerotic cardiovascular disease (ASCVD). The research examines advanced therapeutic approaches for reducing major adverse cardiovascular events in high-risk patients.
This groundbreaking research aims to evaluate new therapeutic strategies for improving cardiovascular outcomes in preventive cardiology, particularly focusing on patients who haven't yet experienced a cardiovascular event.
Tell us about your condition – we search every trial in Europe and connect you with the right site.